ClinicalTrials.gg
RecruitingNCT07017699Updated Oct 1, 2026

A Study to Assess Deucravacitinib Safety in Pregnancy

An observational study in Psoriasis (PsO), sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
900
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.

Planned enrollment
4th of 14
900 · median 528
Started
2025
with 6 others
Observational
14 of 42
5 open now
Primary completion
2028-04
later than 5 of 13 live
Registered
39th of 42
by date

Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 4th largest by planned enrollment of the 14 observational ones that give a count, is one of 7 that started in 2025, is one of 14 observational ones, reaches primary completion later than 5 of the 13 other live ones, and was the 39th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Psoriasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were exposed to deucravacitinib.

03

Conditions studied

  • Psoriasis (PsO)

Browse trials for

Keywords

  • Psoriasis (PsO)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will include pregnant women participating in the The Organization of Teratology Information Specialists (OTIS) pregnancy registry in the US or Canada

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1: Deucravacitinib-exposed cohort

  • Currently pregnant during the enrollment period
  • Diagnosed with psoriasis (PsO) validated by medical records when possible
  • Exposure to deucravacitinib for any number of days, at any dose, and at any time from 2 days prior to date of conception (DOC) to the end of pregnancy
  • Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants

Cohort 2: PsO Disease-matched unexposed comparator cohort

  • Currently pregnant during the enrollment period
  • Diagnosed with PsO validated by medical records when possible
  • May be exposed to systemic treatments for PsO
  • Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants

Cohort 3: Non-disease unexposed comparator cohort

  • Currently pregnant during the enrollment period
  • Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants

Exclusion criteria

Exclusion Criteria

Cohort 1: Deucravacitinib-exposed cohort

  • Pregnant women who have enrolled in this cohort study with a previous pregnancy
  • Pregnant women who have used deucravacitinib for an indication other than PsO
  • Women who do not have exposure to deucravacitinib anytime from 2 days prior to DOC to the end of pregnancy
  • Women who have exposure to another oral tyrosine kinase 2 (TYK2) inhibitor or any oral Janus kinase (JAK) inhibitor from within 5 half-lives of DOC to the end of pregnancy
  • Women who have exposure to methotrexate or an oral retinoid
  • Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)
  • Results of a diagnostic test are positive for an major congenital malformation(s) (MCM) prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM

Cohort 2: Disease-matched unexposed comparator cohort

  • Pregnant women who have enrolled in this cohort study with a previous pregnancy
  • Women who have exposure to deucravacitinib or any other oral TYK2 inhibitor except deucravacitinib, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy
  • Women who have exposure to methotrexate or an oral retinoid
  • Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)
  • Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM

Cohort 3: Non-disease unexposed comparator cohort

  • Pregnant women who have enrolled in this cohort study with a previous pregnancy
  • Women who have had exposure to deucravacitinib or any other oral TYK2 inhibitor, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy
  • Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)
  • Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM
  • Women exposed to a known, possible, or suspected human teratogen during pregnancy as confirmed by the OTIS Research Center (see Appendix 3 for list of known, possible, and suspected human teratogens)
  • Women who are diagnosed with PsO, or any other disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
900 participants (estimated)
Patient registry
No

Groups and cohorts

  • Deucravacitinib Cohort

    Pregnant participants with psoriasis exposed to deucravacitinib treatment

    Drug: Deucravacitinib

  • Other Systemic Treatment Cohort

    Pregnant participants with psoriasis exposed to other systemic treatments for PsO

    Drug: Other systemic treatments for PsO

  • Unexposed Cohort

    Pregnant participants without psoriasis or any other autoimmune diseases

Interventions

  • According to product label

  • DrugOther systemic treatments for PsO

    According to product label

06

What researchers measure

Primary outcomes

  1. Number of major congenital malformations among infants

    Time frame: 1-year post pregnancy outcome

Secondary outcomes

  1. Number of other pregnancy and infant outcomes

    Other pregnancy and infant outcomes include: * Minor congenital malformations, * Small for gestational age * Small for age postnatal growth at 1 year of age * Serious or opportunistic infections * Neonatal hospitalization * Infant deaths * Neonatal deaths * Perinatal deaths * Spontaneous abortions * Stillbirths * Elective terminations/abortions * Preterm deliveries * Preeclampsia/eclampsia * Gestational hypertension

    Time frame: 1-year post pregnancy outcome

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.

Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 36 months is close to that.

Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartActual
Mar 21, 2025
Primary completionEst.
Apr 1, 2028
CompletionEst.
Feb 28, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and verification date
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07017699
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Mar 21, 2025
Primary completion
Apr 1, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion